A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon .

Trial Profile

A Phase III, Long-Term Treatment Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon .

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Oct 2015 New trial record
    • 07 Oct 2015 According to a Meiji media release, this trial has been initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top